Three Seasons Wealth LLC Raises Stock Position in Pacira BioSciences, Inc. $PCRX

Three Seasons Wealth LLC raised its position in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 43.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 62,942 shares of the company’s stock after purchasing an additional 19,107 shares during the quarter. Three Seasons Wealth LLC’s holdings in Pacira BioSciences were worth $1,597,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. AXQ Capital LP acquired a new stake in shares of Pacira BioSciences during the 2nd quarter worth approximately $243,000. Hsbc Holdings PLC lifted its holdings in Pacira BioSciences by 48.0% in the second quarter. Hsbc Holdings PLC now owns 29,482 shares of the company’s stock valued at $747,000 after acquiring an additional 9,560 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Pacira BioSciences by 17.8% in the second quarter. Wellington Management Group LLP now owns 563,458 shares of the company’s stock valued at $14,295,000 after acquiring an additional 85,075 shares during the last quarter. Empowered Funds LLC acquired a new position in Pacira BioSciences in the second quarter valued at approximately $5,076,000. Finally, Caitlin John LLC purchased a new position in Pacira BioSciences in the second quarter worth approximately $120,000. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Insider Activity

In other news, insider Jonathan Slonin sold 3,040 shares of Pacira BioSciences stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $23.23, for a total value of $70,619.20. Following the completion of the transaction, the insider owned 216,384 shares in the company, valued at approximately $5,026,600.32. This trade represents a 1.39% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Lauren Riker sold 6,115 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $23.50, for a total transaction of $143,702.50. Following the sale, the senior vice president owned 62,284 shares in the company, valued at $1,463,674. The trade was a 8.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Royal Bank Of Canada raised their target price on Pacira BioSciences from $24.00 to $25.00 and gave the stock a “sector perform” rating in a research note on Wednesday, August 5th. Wall Street Zen cut Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Sunday, August 16th. Needham & Company LLC upped their target price on shares of Pacira BioSciences from $32.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. HC Wainwright reaffirmed a “buy” rating and set a $38.00 target price on shares of Pacira BioSciences in a research note on Wednesday, July 1st. Finally, Truist Financial began coverage on shares of Pacira BioSciences in a research note on Monday, August 17th. They issued a “buy” rating and a $30.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, Pacira BioSciences presently has an average rating of “Hold” and a consensus target price of $30.20.

Pacira BioSciences Stock Down 0.9%

Pacira BioSciences stock opened at $26.35 on Friday. The firm has a market capitalization of $1.05 billion, a P/E ratio of 75.29 and a beta of 0.26. The company has a current ratio of 5.04, a quick ratio of 3.94 and a debt-to-equity ratio of 0.54. Pacira BioSciences, Inc. has a twelve month low of $18.80 and a twelve month high of $27.66. The stock’s fifty day simple moving average is $25.43 and its 200-day simple moving average is $24.00.

Pacira BioSciences (NASDAQ:PCRX) last released its earnings results on Tuesday, August 4th. The company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.65 by $0.08. Pacira BioSciences had a return on equity of 9.68% and a net margin of 1.96%.The firm had revenue of $192.40 million during the quarter, compared to analysts’ expectations of $191.06 million. During the same period in the previous year, the firm posted $0.74 EPS. Pacira BioSciences’s revenue for the quarter was up 6.2% on a year-over-year basis. As a group, equities analysts expect that Pacira BioSciences, Inc. will post 1.98 earnings per share for the current fiscal year.

Pacira BioSciences Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.